Angiotensin II improves random-flap viability in a rat model

Area of Science:

• Wound healing research
• Vascular biology
• Tissue engineering

Background:

• Angiotensin II (AII) is a peptide with known angiogenic and tissue repair properties.
• Previous studies indicate AII promotes cell proliferation and extracellular matrix production.
• The efficacy of AII in enhancing flap survival requires further investigation.

Purpose of the Study:

• To evaluate the effect of a single Angiotensin II (AII) administration on random flap viability and vascularity in a rat model.
• To determine the optimal dosage and vehicle for AII in promoting flap survival.

Main Methods:

• Random flaps in rats were treated with varying doses of Angiotensin II (AII) in phosphate-buffered saline (PBS) or carboxymethyl cellulose (CMC) vehicle.
• Flap viability and percentage of survival were assessed post-surgery.
• Dose-response relationships were analyzed to identify effective AII concentrations.

Main Results:

• A single administration of higher dose AII (10 mg/mL in PBS or 1 mg/mL in CMC) significantly increased flap viability by day 12 compared to controls.
• A dose as low as 0.03 mg/mL AII in CMC demonstrated significant improvement in flap survival.
• The percentage of viable flap area also increased significantly with AII treatment.

Conclusions:

• Angiotensin II (AII) is highly effective in increasing distal flap surface area survival.
• A single topical dose of AII to the wound bed significantly enhances random flap viability.
• AII demonstrates potential as a therapeutic agent for improving outcomes in reconstructive surgery and wound healing.